+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "CAR T Cell"

From
From
From
Global Immuno-oncology Market - Product Thumbnail Image

Global Immuno-oncology Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Global CAR T-Cell Therapy Market 2023-2027 - Product Thumbnail Image

Global CAR T-Cell Therapy Market 2023-2027

  • Report
  • May 2023
  • 153 Pages
  • Global
From
From
USA Solid Tumor Therapeutics Market Outlook to 2028 - Product Thumbnail Image

USA Solid Tumor Therapeutics Market Outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
Loading Indicator

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells. CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors. CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more